Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of mild Alzheimer's Disease~* Mini-Mental State Examination (MMSE) scores between 20 and 26 (inclusive)~* Clinical dementia rating (CDR) scores of 0.5 or 1~* Other inclusion criteria apply~Exclusion Criteria:~* Clinically significant neurological disease other than Alzheimer's disease~* Major psychiatric disorder~* Severe systemic disease~* Serious adverse reactions to any vaccine~* Other exclusion criteria apply

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 3 priming doses followed by 4 boosters (Type: EXPERIMENTAL): Subjects will receive 7 doses of UB-311.
- 3 priming doses followed by 2 boosters (Type: EXPERIMENTAL): Subjects will receive 5 doses of UB-311 and 2 doses of placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive 7 doses of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).